However, future studies should further explore the functional relevance of cell type-specific differential splicing in FLT3-ITD+/NPM1+ AML cells in order to determine their impact on response to treatment and usefulness as novel therapeutic targets. This evidence concerns the gene FLT3 and acute myeloid leukemia.